SOUTH SAN FRANCISCO, Calif., June 23, 2025 - CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) announced the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of its lead compound, CER-1236. The trial, titled "Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia (CertainT-1)," is designed to assess the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia. Preliminary results from the trial's Dose Escalation Safety Committee indicate that the first patient demonstrated no dose-limiting toxicity during the 28-day observation period. The company plans to dose a second patient in the cohort shortly. CERo has announced plans to initiate a second trial of CER-1236 in solid tumors later this year. Further updates on the trial's progress will be provided in the future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。